Table 4 Chemotherapy response assessment
| Differentiation status | PLR | NLR | cNPS | cNPLDS | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| well/moderate | poor | ≤223 | > 223 | ≤3.04 | > 3.04 | 1 | 2 | 3 | 1–2 | 3–4 | 6–9 | |
| Total | 46 | 90 | 89 | 47 | 81 | 55 | 69 | 32 | 35 | 27 | 55 | 54 |
| CR |
0 (0%) |
0 (0%) |
0 (0%) |
0 (0%) |
0 (0%) |
0 (0%) |
0 (0%) |
0 (0%) |
0 (0%) |
0 (0%) |
0 (0%) |
0 (0%) |
| PR |
3 (6.52%) |
4 (4.44%) |
4 (4.49%) |
3 (6.38%) |
3 (3.70%) |
4 (7.27%) |
2 (2.90%) |
3 (9.38%) |
2 (5.71%) |
2 (7.41%) |
1 (1.82%) |
4 (7.41%) |
| SD |
36 (78.26%) |
64 (71.11%) |
72 (80.89%) |
28 (59.57%) |
68 (83.95%) |
32 (58.18%) |
59 (85.51%) |
22 (68.75%) |
17 (48.57%) |
23 (85.19%) |
46 (83.64%) |
31 (57.41%) |
| PD |
7 (15.21%) |
22 (24.44%) |
13 (14.61%) |
16 (34.04%) |
10 (12.34%) |
19 (34.55%) |
8 (11.59%) |
7 (21.87%) |
14 (40%) |
2 (7.41%) |
8 (14.55%) |
19 (35.19%) |
| DCR | 84.78% | 75.56% | 85.39% | 65.96% | 87.65% | 65.45% | 88.40% | 78.13% | 60% | 92.59% | 85.45% | 64.81% |
| P | 0.214 | 0.008 | 0.002 | 0.004 | 0.004 | |||||||